Drugs / ALC01
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07212088 | Feb 2026 → Dec 2027 expected | Parkinson disease | iCamuno Biotherapeutics Ltd. | Not yet recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ALC01 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07212088 ↗ |
| Action | Restore | “to restore dopamine-producing capacity” NCT07212088 ↗ |
| Modality | Cell therapy | “allogenic induced pluripotent stem cell-derived dopamine progenitor cells (iPSC-DAPs)” NCT07212088 ↗ |
| Route | Other | “administered into the putamen on each side of the brain” NCT07212088 ↗ |